Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin

There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation, neutralization, and acute reactions associated with drug delivery systems. Published and commercially available anti-PEG enzyme-linked immunosorbent a...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 21; no. 6; pp. 3053 - 3060
Main Authors Li, Yue, Ettah, Utibeabasi, Jacques, Sarah, Gaikwad, Hanmant, Monte, Andrew, Dylla, Layne, Guntupalli, Saketh, Moghimi, S. Moein, Simberg, Dmitri
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 03.06.2024
Subjects
Adult
Doxorubicin - analogs & derivatives
Doxorubicin - therapeutic use
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G - blood
Immunoglobulin G - immunology
Immunoglobulin M - blood
Immunoglobulin M - immunology
Liposomes
Male
Middle Aged
Neoplasms - drug therapy
Neoplasms - immunology
Polyethylene Glycols - therapeutic use
PEGylated liposomal doxorubicin
Doxil
PEG
specific
patients
ELISA
Online AccessGet full text

Cover

Abstract There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation, neutralization, and acute reactions associated with drug delivery systems. Published and commercially available anti-PEG enzyme-linked immunosorbent assays (ELISAs) differ significantly in terms of reagents and conditions, which could be confusing to users who want to perform in-house measurements. Here, we optimize the ELISA protocol for specific detection of anti-PEG IgG and IgM in sera from healthy donors and in plasma from cancer patients administered with PEGylated liposomal doxorubicin. The criterion of specificity is the ability of free PEG or PEGylated liposomes to inhibit the ELISA signals. We found that coating high-binding plates with monoamine methoxy-PEG5000, as opposed to bovine serum albumin-PEG20000, and blocking with 1% milk, as opposed to albumin or lysozyme, significantly improve the specificity, with over 95% of the signal being blocked by competition. Despite inherent between-assay variability, setting the cutoff value of the optical density at the 80th percentile consistently identified the same subjects. Using the optimized assay, we longitudinally measured levels of anti-PEG IgG/IgM in cancer patients before and after the PEGylated liposomal doxorubicin chemotherapy cycle (1 month apart, three cycles total). Antibody titers did not show any increase but rather a decrease between treatment cycles, and up to 90% of antibodies was bound to the infused drug. This report is a step toward harmonizing anti-PEG assays in human subjects, emphasizing the cost-effectiveness and optimized specificity.
AbstractList There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation, neutralization, and acute reactions associated with drug delivery systems. Published and commercially available anti-PEG enzyme-linked immunosorbent assays (ELISAs) differ significantly in terms of reagents and conditions, which could be confusing to users who want to perform in-house measurements. Here, we optimize the ELISA protocol for specific detection of anti-PEG IgG and IgM in sera from healthy donors and in plasma from cancer patients administered with PEGylated liposomal doxorubicin. The criterion of specificity is the ability of free PEG or PEGylated liposomes to inhibit the ELISA signals. We found that coating high-binding plates with monoamine methoxy-PEG , as opposed to bovine serum albumin-PEG , and blocking with 1% milk, as opposed to albumin or lysozyme, significantly improve the specificity, with over 95% of the signal being blocked by competition. Despite inherent between-assay variability, setting the cutoff value of the optical density at the 80th percentile consistently identified the same subjects. Using the optimized assay, we longitudinally measured levels of anti-PEG IgG/IgM in cancer patients before and after the PEGylated liposomal doxorubicin chemotherapy cycle (1 month apart, three cycles total). Antibody titers did not show any increase but rather a decrease between treatment cycles, and up to 90% of antibodies was bound to the infused drug. This report is a step toward harmonizing anti-PEG assays in human subjects, emphasizing the cost-effectiveness and optimized specificity.
There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation, neutralization, and acute reactions associated with drug delivery systems. Published and commercially available anti-PEG enzyme-linked immunosorbent assays (ELISAs) differ significantly in terms of reagents and conditions, which could be confusing to users who want to perform in-house measurements. Here, we optimize the ELISA protocol for specific detection of anti-PEG IgG and IgM in sera from healthy donors and in plasma from cancer patients administered with PEGylated liposomal doxorubicin. The criterion of specificity is the ability of free PEG or PEGylated liposomes to inhibit the ELISA signals. We found that coating high-binding plates with monoamine methoxy-PEG5000, as opposed to bovine serum albumin-PEG20000, and blocking with 1% milk, as opposed to albumin or lysozyme, significantly improve the specificity, with over 95% of the signal being blocked by competition. Despite inherent between-assay variability, setting the cutoff value of the optical density at the 80th percentile consistently identified the same subjects. Using the optimized assay, we longitudinally measured levels of anti-PEG IgG/IgM in cancer patients before and after the PEGylated liposomal doxorubicin chemotherapy cycle (1 month apart, three cycles total). Antibody titers did not show any increase but rather a decrease between treatment cycles, and up to 90% of antibodies was bound to the infused drug. This report is a step toward harmonizing anti-PEG assays in human subjects, emphasizing the cost-effectiveness and optimized specificity.
There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation, neutralization, and acute reactions associated with drug delivery systems. Published and commercially available anti-PEG enzyme-linked immunosorbent assays (ELISAs) differ significantly in terms of reagents and conditions, which could be confusing to users who want to perform in-house measurements. Here, we optimize the ELISA protocol for specific detection of anti-PEG IgG and IgM in sera from healthy donors and in plasma from cancer patients administered with PEGylated liposomal doxorubicin. The criterion of specificity is the ability of free PEG or PEGylated liposomes to inhibit the ELISA signals. We found that coating high-binding plates with monoamine methoxy-PEG5000, as opposed to bovine serum albumin-PEG20000, and blocking with 1% milk, as opposed to albumin or lysozyme, significantly improve the specificity, with over 95% of the signal being blocked by competition. Despite inherent between-assay variability, setting the cutoff value of the optical density at the 80th percentile consistently identified the same subjects. Using the optimized assay, we longitudinally measured levels of anti-PEG IgG/IgM in cancer patients before and after the PEGylated liposomal doxorubicin chemotherapy cycle (1 month apart, three cycles total). Antibody titers did not show any increase but rather a decrease between treatment cycles, and up to 90% of antibodies was bound to the infused drug. This report is a step toward harmonizing anti-PEG assays in human subjects, emphasizing the cost-effectiveness and optimized specificity.There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation, neutralization, and acute reactions associated with drug delivery systems. Published and commercially available anti-PEG enzyme-linked immunosorbent assays (ELISAs) differ significantly in terms of reagents and conditions, which could be confusing to users who want to perform in-house measurements. Here, we optimize the ELISA protocol for specific detection of anti-PEG IgG and IgM in sera from healthy donors and in plasma from cancer patients administered with PEGylated liposomal doxorubicin. The criterion of specificity is the ability of free PEG or PEGylated liposomes to inhibit the ELISA signals. We found that coating high-binding plates with monoamine methoxy-PEG5000, as opposed to bovine serum albumin-PEG20000, and blocking with 1% milk, as opposed to albumin or lysozyme, significantly improve the specificity, with over 95% of the signal being blocked by competition. Despite inherent between-assay variability, setting the cutoff value of the optical density at the 80th percentile consistently identified the same subjects. Using the optimized assay, we longitudinally measured levels of anti-PEG IgG/IgM in cancer patients before and after the PEGylated liposomal doxorubicin chemotherapy cycle (1 month apart, three cycles total). Antibody titers did not show any increase but rather a decrease between treatment cycles, and up to 90% of antibodies was bound to the infused drug. This report is a step toward harmonizing anti-PEG assays in human subjects, emphasizing the cost-effectiveness and optimized specificity.
Author Monte, Andrew
Jacques, Sarah
Gaikwad, Hanmant
Dylla, Layne
Guntupalli, Saketh
Ettah, Utibeabasi
Moghimi, S. Moein
Li, Yue
Simberg, Dmitri
AuthorAffiliation University of Colorado Anschutz Medical Campus
Translational and Clinical Research Institute, Faculty of Health and Medical Sciences
Department of Emergency Medicine
University of Colorado School of Medicine Anschutz Medical Campus
School of Pharmacy
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences
Newcastle University
Colorado Center for Nanomedicine and Nanosafety
AuthorAffiliation_xml – name: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
– name: University of Colorado School of Medicine Anschutz Medical Campus
– name: Colorado Center for Nanomedicine and Nanosafety
– name: University of Colorado Anschutz Medical Campus
– name: Newcastle University
– name: Department of Emergency Medicine
– name: School of Pharmacy
– name: Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences
– name: Translational and Clinical Research Institute, Faculty of Health and Medical Sciences
Author_xml – sequence: 1
  givenname: Yue
  surname: Li
  fullname: Li, Yue
  organization: Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences
– sequence: 2
  givenname: Utibeabasi
  surname: Ettah
  fullname: Ettah, Utibeabasi
  organization: Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences
– sequence: 3
  givenname: Sarah
  surname: Jacques
  fullname: Jacques, Sarah
  organization: Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences
– sequence: 4
  givenname: Hanmant
  surname: Gaikwad
  fullname: Gaikwad, Hanmant
  organization: University of Colorado Anschutz Medical Campus
– sequence: 5
  givenname: Andrew
  surname: Monte
  fullname: Monte, Andrew
  organization: University of Colorado Anschutz Medical Campus
– sequence: 6
  givenname: Layne
  surname: Dylla
  fullname: Dylla, Layne
  organization: University of Colorado Anschutz Medical Campus
– sequence: 7
  givenname: Saketh
  surname: Guntupalli
  fullname: Guntupalli, Saketh
  organization: University of Colorado School of Medicine Anschutz Medical Campus
– sequence: 8
  givenname: S. Moein
  orcidid: 0000-0003-0836-926X
  surname: Moghimi
  fullname: Moghimi, S. Moein
  organization: Newcastle University
– sequence: 9
  givenname: Dmitri
  orcidid: 0000-0002-5288-6275
  surname: Simberg
  fullname: Simberg, Dmitri
  email: dmitri.simberg@cuanschutz.edu
  organization: University of Colorado Anschutz Medical Campus
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38743264$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1u1DAUhS1URH_gFZDZscngv0wyKzQqQ1tppHZR1taN7WhcYjvYjiB9EV4XT2eKBKsuLPta3zlXOuccnfjgDUIfKFlQwugnUGnhwjDuIDpQZsoLoQhhTfsKndFa8KrlK3by992KU3Se0kNBRM34G3TK20ZwthRn6PftmK2zj0bjjX-cnam21n8v041zkw8pxM74jNcpwYz7EPHaZ1vdba6eHl3QM_5islHZBo-tx9cGhrwrn8GHmDB4je8g2-KR8H00kIv1T5t3uFjMw9O4tWPZ42Aool8hTp1V1r9Fr3sYknl3vC_Qt6-b-8vrant7dXO53lYgqMiVFqLhnW5VD6zmTa3KaXVLjeaNqDvgDMBwvaScNbwHIJwSyoghSyUarTS_QB8PvmMMPyaTsnQ2KTMM4E2YkuSkrktoK8IK-v6ITp0zWo7ROoizfA6zAJ8PgIohpWh6qWyGfTI5gh0kJXJfnyz1yX_qk8f6isPqP4fnJS_R1gftHnkIU_Qltxfo_gCqn7yJ
CitedBy_id crossref_primary_10_1021_acsnano_4c05087
crossref_primary_10_3390_jnt5030007
Cites_doi 10.1016/j.jconrel.2024.01.003
10.1021/acsnano.1c05922
10.1016/j.jconrel.2022.12.039
10.1016/j.ijpharm.2012.07.049
10.1111/j.1538-7836.2006.01753.x
10.1016/j.vaccine.2023.06.009
10.1002/wnan.1339
10.1021/acsnano.9b07218
10.1021/acs.analchem.6b03437
10.1002/cncr.22739
10.1007/s00280-011-1664-2
10.1177/0961203312460722
10.1016/j.chembiol.2019.02.001
10.1111/bjh.16254
10.1021/bc980143z
10.1021/acs.analchem.6b03109
10.1016/j.thromres.2006.07.014
10.1016/j.jim.2019.112669
10.3389/fimmu.2023.1087532
10.1016/j.jconrel.2021.11.042
10.1039/D3NH00198A
10.1016/B978-0-08-101750-0.00003-9
10.1016/j.jaci.2009.09.046
10.3390/molecules23071700
10.1038/nnano.2016.269
10.1021/acsnano.2c04543
10.1016/j.jconrel.2006.08.017
10.1248/bpb.b13-00107
10.1002/btm2.10600
10.1159/000233512
10.1016/j.jconrel.2023.01.021
10.1016/j.addr.2021.114079
ContentType Journal Article
Copyright 2024 American Chemical Society
Copyright_xml – notice: 2024 American Chemical Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1021/acs.molpharmaceut.4c00278
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1543-8392
EndPage 3060
ExternalDocumentID 38743264
10_1021_acs_molpharmaceut_4c00278
a039222143
Genre Journal Article
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: R01 AI154959
– fundername: NIGMS NIH HHS
  grantid: R35 GM152157
GroupedDBID ---
-~X
123
4.4
53G
55A
5VS
7~N
AABXI
ABJNI
ABMVS
ABQRX
ABUCX
ACGFS
ACS
ADHLV
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
CUPRZ
DU5
EBS
ED~
F5P
GGK
GNL
H~9
IH9
JG~
P2P
RNS
ROL
UI2
VF5
VG9
W1F
AAYXX
ABBLG
ABLBI
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-a414t-d4473bd8cfa25375c3758d81ed3745ba32aae3d613273faa0310120e06c47dcd3
IEDL.DBID ACS
ISSN 1543-8384
1543-8392
IngestDate Fri Jul 11 02:52:45 EDT 2025
Sat May 31 02:13:25 EDT 2025
Tue Jul 01 02:22:44 EDT 2025
Thu Apr 24 23:11:26 EDT 2025
Tue Jun 04 11:04:22 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords PEGylated liposomal doxorubicin
Doxil
PEG
specific
patients
ELISA
Language English
License https://doi.org/10.15223/policy-029
https://doi.org/10.15223/policy-037
https://doi.org/10.15223/policy-045
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a414t-d4473bd8cfa25375c3758d81ed3745ba32aae3d613273faa0310120e06c47dcd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-0836-926X
0000-0002-5288-6275
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/12109707
PMID 38743264
PQID 3055452902
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_3055452902
pubmed_primary_38743264
crossref_citationtrail_10_1021_acs_molpharmaceut_4c00278
crossref_primary_10_1021_acs_molpharmaceut_4c00278
acs_journals_10_1021_acs_molpharmaceut_4c00278
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-06-03
PublicationDateYYYYMMDD 2024-06-03
PublicationDate_xml – month: 06
  year: 2024
  text: 2024-06-03
  day: 03
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2024
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref3/cit3
ref27/cit27
ref18/cit18
ref11/cit11
ref25/cit25
ref16/cit16
ref29/cit29
ref32/cit32
ref23/cit23
ref14/cit14
ref8/cit8
ref5/cit5
ref31/cit31
ref2/cit2
ref34/cit34
ref28/cit28
Abu Lila A. S. (ref6/cit6) 2018
ref20/cit20
ref17/cit17
ref10/cit10
ref26/cit26
ref19/cit19
ref21/cit21
ref12/cit12
ref15/cit15
ref22/cit22
ref13/cit13
ref33/cit33
ref4/cit4
ref30/cit30
ref1/cit1
ref24/cit24
ref7/cit7
References_xml – ident: ref18/cit18
  doi: 10.1016/j.jconrel.2024.01.003
– ident: ref4/cit4
  doi: 10.1021/acsnano.1c05922
– ident: ref34/cit34
  doi: 10.1016/j.jconrel.2022.12.039
– ident: ref5/cit5
  doi: 10.1016/j.ijpharm.2012.07.049
– ident: ref28/cit28
  doi: 10.1111/j.1538-7836.2006.01753.x
– ident: ref16/cit16
  doi: 10.1016/j.vaccine.2023.06.009
– ident: ref10/cit10
  doi: 10.1002/wnan.1339
– ident: ref33/cit33
  doi: 10.1021/acsnano.9b07218
– ident: ref12/cit12
  doi: 10.1021/acs.analchem.6b03437
– ident: ref20/cit20
  doi: 10.1016/j.ijpharm.2012.07.049
– ident: ref9/cit9
  doi: 10.1002/cncr.22739
– ident: ref22/cit22
  doi: 10.1007/s00280-011-1664-2
– ident: ref26/cit26
  doi: 10.1177/0961203312460722
– ident: ref31/cit31
  doi: 10.1016/j.chembiol.2019.02.001
– ident: ref32/cit32
  doi: 10.1111/bjh.16254
– ident: ref29/cit29
  doi: 10.1021/bc980143z
– ident: ref11/cit11
  doi: 10.1021/acs.analchem.6b03109
– ident: ref27/cit27
  doi: 10.1016/j.thromres.2006.07.014
– ident: ref15/cit15
  doi: 10.1016/j.jim.2019.112669
– ident: ref24/cit24
  doi: 10.3389/fimmu.2023.1087532
– ident: ref30/cit30
  doi: 10.1016/j.jconrel.2021.11.042
– ident: ref13/cit13
  doi: 10.1039/D3NH00198A
– start-page: 51
  volume-title: Engineering of Biomaterials for Drug Delivery Systems
  year: 2018
  ident: ref6/cit6
  doi: 10.1016/B978-0-08-101750-0.00003-9
– ident: ref23/cit23
  doi: 10.1016/j.jaci.2009.09.046
– ident: ref14/cit14
  doi: 10.3390/molecules23071700
– ident: ref17/cit17
  doi: 10.1038/nnano.2016.269
– ident: ref8/cit8
  doi: 10.1021/acsnano.2c04543
– ident: ref19/cit19
  doi: 10.1016/j.jconrel.2006.08.017
– ident: ref21/cit21
  doi: 10.1248/bpb.b13-00107
– ident: ref1/cit1
  doi: 10.1002/btm2.10600
– ident: ref3/cit3
  doi: 10.1159/000233512
– ident: ref25/cit25
  doi: 10.1016/j.jconrel.2023.01.021
– ident: ref2/cit2
  doi: 10.1016/j.addr.2021.114079
– ident: ref7/cit7
  doi: 10.1016/j.jconrel.2022.12.039
SSID ssj0024523
Score 2.4575655
Snippet There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation,...
SourceID proquest
pubmed
crossref
acs
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3053
SubjectTerms Adult
Doxorubicin - analogs & derivatives
Doxorubicin - therapeutic use
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G - blood
Immunoglobulin G - immunology
Immunoglobulin M - blood
Immunoglobulin M - immunology
Liposomes
Male
Middle Aged
Neoplasms - drug therapy
Neoplasms - immunology
Polyethylene Glycols - therapeutic use
Title Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin
URI http://dx.doi.org/10.1021/acs.molpharmaceut.4c00278
https://www.ncbi.nlm.nih.gov/pubmed/38743264
https://www.proquest.com/docview/3055452902
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Za9wwEBZtCqUvvY_thQIlT9HWlmRbfgzJpmnpsdAN5M3oMizNSmHthXr_SP9uR7I3S1pKkweDJawxQjOez5qZTwi9K6wxJc0VkaKkhMskI2UpKaHSKK10LspY4f3la35yyj-dZWfbOu4_I_g0fS91M174UHg6bPGOuY7xstvoDs3BmAMeOvy-JdjL4pluAA0YEUzwu2j3v6KCa9LNVdf0D7wZ_c7xAzTbVO_06SY_xqtWjfX6bzLHm0zpIbo_4FB80CvOI3TLusdob9o_2-3j2bYuq9nHe3i6pbjunqBf3-BLs5ivrcETt-4WloR_Wmh9DOUmvvFLBc4Mw9rLDgMsxgeunZPp5EO8Ud50-Mi2MQvM4bnDfTEUdHrnlw2WzuBpT_ja4FmAtSA67BhjENGdx-bn-QW8ZwFzOPI__XKlQorAU3R6PJkdnpDhiAciecpbYjgvmDJC15JmrMg0XMKI1BpW8ExJRqW0zADmAJhVSxmITFOa2CTXvDDasGdox3lnXyCc1knNCp3wGiBLXluZl6miSmWq5FKl-QiBhjbVYKJNFaPvNK1C55XFqIbFGCGxUYdKD4Tp4dyO8-sMpZdDL3rWkOsM2t3oXAU2HgI30lm_aqrAyhYC5Akdoee9Ml6KZQIwIKDalzed3it0j4K1xLQ39hrttMuVfQMAq1Vvo0H9BnPPKQQ
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZbB9teuvuaXVUYfapTW5Jvj6FNl25pF1gKhT0Y3QxhjVRiB-b8kf3dHcluQgdj3R4MlrCOJXSO9VnnnE8IfUi1UjlJRMCznASMh3GQ55wEhCshhUyy3Gd4n54lo3P26SK-6KIqXS4MdKICSZV34m_YBaIDVze3Lv-02-ntM-ndZnfRPQAlxGn34PDrhmcv9ke7AUKgQUYzdh_t_lWUW6FkdXOF-gPs9MvP8SP0bd1xH3Xyvb-sRV-ufuN0_L-RPUbbHSrFg1aNnqA72jxFe5P22WYfTzdZWtU-3sOTDeF18wz9_ALfnflspRUemlUz14H7w4XSiUs-sZVdCFjaMGgCbzCAZDww9SyYDD_6G2FVg4907WPCDJ4Z3KZGQaU1dlFhbhSetPSvFZ46kAui3f4xBhHNpS-OZ1fwnjmM4cj-sIulcAEDz9H58XB6OAq6Ax8CziJWB4qxlAqVyZKTmKaxhCtTWaQVTVksOCWca6oAgQDoKjl3tKYRCXWYSJYqqegLtGWs0TsIR2VY0lSGrAQAk5SaJ3kkiBCxyBkXUdJDbi6KzmCrwvviSVS4yhuTUXST0UPZtVYUsqNPd6d4XN6mKVk3vWo5RG7TaPda9QqweOfG4UbbZVU4jjbnLg9JD71sdXItlmaACAHjvvrX4b1HD0bT03ExPjn7_Bo9JGBAPiCOvkFb9WKp3wL0qsU7b2O_AHVnMWU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZbB2Uv6-5Ld1Nh9KlKbUm-PYYmWbt1XWAp9M3oZghrrBA7MOeP7O_uSHYTOhjr9mCwhHUsoXOszzrnfELoQ2K0zmgsiUgzSrgIIpJlghIqtFRSxWnmM7y_XMSnl_zTVXTVbbi5XBjoRAWSKu_Ed1a90EXHMBAeu_q5dTmo3W5vnyvvOruPHjj3ndPwwcm3Ldde5I93A5TASMpSvosO_irKrVKqur1K_QF6-iVovIfyTed95Mn3_qqWfbX-jdfx_0f3GD3q0CketOr0BN0z5VN0OGmfbY7wdJutVR3hQzzZEl83z9DPr_D9mc_WRuNRuW7mhrg_XSiduSQUW9mlhCUOg0aIBgNYxoOynpHJ6KO_kVY3eGhqHxtW4lmJ2xQpqLSlXVZYlBpPWhrYCk8d2AXRbh8Zg4jm2hfPZwt4zxzGMLQ_7HIlXeDAc3Q5Hk1PTkl38AMRPOQ10ZwnTOpUFYJGLIkUXKlOQ6NZwiMpGBXCMA1IBMBXIYSjNw1pYIJY8UQrzV6gndKW5hXCYREULFEBLwDIxIURcRZKKmUkMy5kGPeQm4-8M9wq9z55Guau8tZk5N1k9FB6oxm56mjU3Wke13dpSjdNFy2XyF0aHdyoXw6W79w5ojR2VeWOq825zQPaQy9bvdyIZSkgQ8C6-_86vPdodzIc5-dnF59fo4cUbMjHxbE3aKdersxbQGC1fOfN7Bf3NDPo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimized+Enzyme-Linked+Immunosorbent+Assay+for+Anti-PEG+Antibody+Detection+in+Healthy+Donors+and+Patients+Treated+with+PEGylated+Liposomal+Doxorubicin&rft.jtitle=Molecular+pharmaceutics&rft.au=Li%2C+Yue&rft.au=Ettah%2C+Utibeabasi&rft.au=Jacques%2C+Sarah&rft.au=Gaikwad%2C+Hanmant&rft.date=2024-06-03&rft.issn=1543-8392&rft.eissn=1543-8392&rft.volume=21&rft.issue=6&rft.spage=3053&rft_id=info:doi/10.1021%2Facs.molpharmaceut.4c00278&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon